Core Viewpoint - The announcement indicates that China National Pharmaceutical Group Modern has received approval for a new drug, tofacitinib citrate tablets, which is expected to enhance its product portfolio in the oncology and immunomodulatory sectors [1] Group 1: Drug Approval and Market Impact - The full subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has obtained the drug registration certificate for tofacitinib citrate tablets from the National Medical Products Administration [1] - Tofacitinib citrate tablets are a novel oral protein tyrosine kinase inhibitor, clinically applicable for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [1] - According to the Meini Network database, the projected sales for public medical institutions in China for 2024 is approximately RMB 477 million [1] Group 2: R&D Investment and Competitive Position - The cumulative R&D investment for the development of tofacitinib citrate tablets by China National Pharmaceutical Group Rongsheng is about RMB 15.5368 million [1] - The approval of the drug registration certificate, which is considered equivalent to passing the consistency evaluation, will enrich the company's formulation product line in the oncology and immunomodulatory fields [1] - This development is expected to enhance the company's comprehensive market competitiveness in related medication areas [1]